Pay in 4 interest-free payments of $5.17 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Neeraj Sharma, CEO and Managing Director, OneSource Specialty Pharma, outlines, The global market for GLP1based therapies is experiencing unprecedented growth, given the increasing incidence of Type 2 diabetes and obesity and its efficacy in the management of both diseases
GIP receptor agonist compounds
This property is of special interest in studies focusing on microvascular repair, ischemia, and circulatory regulation under chemically induced injury or surgical conditions
Meals become less emotionally charged
Initially approved for glycemic control in type 2 diabetes mellitus, their clinical application has expanded into obesity management, cardiovascular risk reduction, and metabolic syndrome modulation
Trendy new weight-loss drugs are unaffordable At the root of the problem is that obesity has long been viewed as a personal failing, not a medical diagnosis
